The experience treatment of adjunctive lacosamide for patients with drug-resistance partial epilepsy

The aim of the study was to evaluate the efficacy and safety of lacosamide (100-400 mg per day) as adjunctive treatment to other antiepileptic drugs (AED) in patients with uncontrolled partial epilepsy. A retrospective evaluation of efficacy and safety of lacosamide was made in 56 patients, aged 17-58 years, with focal seizures with- or without secondary localization during 6 months. Lacosamide was used with other AED (carbamazepine, oxcarbazepine, lamotrigine, valproates, levetiracetam, topiramate); in 73,2% patients it was administered with two additional AED. In 69,6% patients, the dose of lacosamide was 300 mg per day. The complete cessation of seizures was achieved in 8 (14,3%) patients, 18 (32,1%) patients had 50-75% reduction in seizures, 17 (30,4%) had 50% reduction. There were no changes in 3 (23,2) patients. Dose-dependent adverse effects were diplopia, vertigo, sleepiness, skin allergic reactions. No side-effects were caused by drug intolerance. Lacosamide is believed to open new possibilities in treatment of epilepsy.